Program

 

To access the sessions recordings, slides and Q&As, we require a registration available from the Registration page.

PUBLISHED APRIL 27Access this here.
Introduction and Welcome NotesHoward Fillit, MD—Alzheimer’s Drug Discovery Foundation
SESSION I. DRUG DISCOVERY 2.0CHAIR: Walter Kostich, PhD—National Multiple Sclerosis Society
Omics to Identify Novel Target for Neurodegenerative Diseases Philip De Jager, MD, PhD—Columbia University
Pre-clinical Science, Clinical Development and Pathway to Marketing Approval of a Living Cell Pharmaceutical for AD – the Mesenchymal Stem/Stromal Cell ParadigmJacques Galipeau, MD—University of Wisconsin, Madison
Shift in Medicinal Chemistry: from Organic Chemistry to Synthetic BiologyEdmund Graziani, PhD—Apertor Labs
SESSION II. DRUG DISCOVERY: FROM TEST TUBE TO ANIMAL STUDIESCHAIR: Nadine Tatton, PhD—The Association for Frontotemporal Degeneration (AFTD)
Compound Optimization after Target Identification: From HTS to LeadKurt Brunden, PhD—University of Pennsylvania
What Can We Still Learn from Studies in Animal Models of Neurodegenerative Disease?Joseph Araujo—InterVivo Solutions
Translational PK/PD in NeurodegenerationNatasha Penner, PhD—Biogen

 

PUBLISHED May 4Access this here.
SESSION III. FROM ANIMAL STUDIES TO HUMAN CLINICAL TRIALSCHAIR: Lilliana Menalled, PhD—The Michael J. Fox Foundation
Requirements for an IND/ToxicologyKenneth Olivier, PhD—Olivier KOnsulting
What are Biomarkers and Why Should I Develop Them?John Gerdes, PhD—Rio Pharma
How to Run a Clinical Trial?Anita DiFrancesco—Samumed
KEYNOTE: The Clinical Potential of Senolytic DrugsJames Kirkland, MD, PhD—Mayo Clinic
SHORT TALKS Brief presentations of scholarship winners and accepted abstract submitters

 

PUBLISHED May 11Access this here.
SESSION IV. I WISH I KNEW... (PRECLINICAL) CHAIR: Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
Case Study: Challenges in Biomarker Development for Huntington's DiseaseDouglas Macdonald, PhD—CHDI Foundation
Case Study: Alzheimer’s Disease Drug Discovery: NMEs vs. NCEs, Pros and Cons of EachAllen Reitz, PhD—ALS Biopharma
Case Study: Challenges in Drug Development for Neurodegenerative DiseaseLeticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
Case Study: Development of Novel Stress Kinase InhibitorD. Martin Watterson, PhD—Northwestern University
SESSION V. CLINICAL CASE STUDIES AND COMMERCIALIZATION STRATEGIESCHAIR: Kuldip Dave, PhD—The ALS Association
Case Study: Challenges Associated with Biomarker Development in Neurodegenerative Conditions – “A Commercial Perspective”Iswariya (Ishu) Venkataraman, PhD—Euroimmun
Case Study: SEMA4D Modulates Blood-Brain Barrier, Microglia, and Inhibits Remyelination in Neurodegenerative DiseaseMaurice Zauderer, PhD—Vaccinex
The Handling of Drug Discovery IP and Paths to CommercializationMaria Emanuel, PhD—University of New Hampshire
Developing your Team and Your Funding StrategyEdward Spack, PhD—Vector BioSolutions/Therini
SHORT TALKS Brief presentations of scholarship winners and accepted abstract submitters

 

SESSION DATES TO BE ANNOUNCED SOON
LIVE: Funding OpportunitiesModerator: Alessio Travaglia, PhD—ADDF

Panelists:
Kuldip Dave, PhD—The ALS Association
David Kemp, President—CurePSP
Walter Kostich, PhD—National Multiple Sclerosis Society
Douglas Macdonald, PhD—CHDI Foundation
Liliana Menalled, PhD—The Michael J. Fox Foundation
Andrew Pieper—Harrington Discovery Institute
Nadine Tatton, PhD—AFTD
Leticia Toledo-Sherman, PhD—Rainwater Charitable Foundation
LIVE: Career PanelModerator: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation

Foundation: Liliana Menalled, PhD—The Michael J. Fox Foundation and Kuldip Dave, PhD—The ALS Association
Government: Charles Cywin, PhD—NINDS
Biotech: Marcie Glicksman, PhD and Edward Spack, PhD—Vector BioSolutions/Therini
Academia: D. Martin Watterson, PhD—Northwestern University
Pharma: Natasha Penner, PhD—Biogen

SCIENTIFIC ADVISORY COMMITTEE

Kurt Brunden, PhD—University of Pennsylvania
Kuldip Dave, PhD—ALS Association
Howard Fillit, MD—ADDF
Lauren Friedman, PhD—ADDF
Marcie Glicksman, PhD
Walter Kostich, PhD—National MS Society
Frank Longo, MD, PhD—Stanford University
Suzana Petanceska, PhD—NIH/NIA
Edward Spack, PhD—Vector BioSolutions/Therini
Alessio Travaglia, PhD—ADDF
D. Martin Watterson, PhD—Northwestern University